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Abstract: The aim of the present review is to survey the accumulated knowledge on the 
extracellular matrix (ECM) of tumors referring to its putative utility as therapeutic target. Fol-
lowing the traditional observation on the extensive morphological alteration in the tumor-affected 
tissue, the well-documented aberrant cellular regulation indicated that ECM components have an 
active role in tumor progression. However, due to the diverse functions and variable expression 
of proteoglycans, matrix proteins, and integrins, it is rather difficult to identify a comprehensive 
therapeutic target among ECM components. At present, the elevated level of heparanase and 
the prominent expression of αvβ5 integrin are considered as promising therapeutic targets. The 
inhibition of glycosaminoglycan offers another promising approach in the treatment of those 
tumors which are stimulated by proteoglycans. It can be ascertained that a selective ECM inhibi-
tor would be a great asset to control metastasis driven by ECM-mediated signaling.
Keywords: tumor microenvironment, tumor progression, three-dimensional ECM, heparan 
sulfate proteoglycan
Introduction
In the multicellular organism, tissue architecture and cellular function are controlled 
by guidance cues derived from the microenvironment composing both cellular and 
molecular elements. Recent studies demonstrated the assembly of extracellular matrix 
(ECM) proteins, proteoglycans (PGs), glycopeptidases, and growth factors to well-
defined structures containing approximately 300 molecules. ECM participates in 
multiple biological events among others in tumor angiogenesis.1,2 ECM, representing a 
network of biopolymers, offers an adynamic tissue-specific structure that is responsible 
for the transmission of extracellular signals to the cells.
Both functions require a highly precise attachment of ECM biopolymers to cells 
executed by the cell surface integrins acting as transmembrane receptors. Several lines 
of investigation concluded that ECM plays an important role in maintaining cellular 
phenotype, ie, ECM biopolymers participate in the retrieval of the gene informa-
tion. Tumor cells – predominantly during metastasis - are exposed to changes of the 
microenvironment. The metabolic reprogramming ability of ECM can be regarded as 
an active contributor to the malignant processes.3,4
ECM in tumor progression
ECM has multiple effects on the biological behaviors of tumors.5,6 It was concluded 
from our previous study that the localization of the tumor in the host organism could 
modify the malignant phenotype of the same tumor.5
Examination of gene expression of ECM components demonstrated that breast 
carcinomas could be classified to four subtypes with different clinical outcomes.7 
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In a xenograft model of human mammary carcinomas, it was 
shown that tumors with low and high metastatic potential 
differ in ECM composition. Several matrix proteins such as 
LTBP3, SNED1, EGLN1, and S100A2 were characteristic 
for the highly metastatic tumors.8 Subtypes of breast and 
colon tumors based upon signature of ECM proteins also 
showed correlation with disease prognosis.9
eCM regulates cell proliferation
In the literature, contradictory findings are published regard-
ing the role of ECM in cell proliferation. There are articles 
reporting enhanced cell proliferation10–17 and others referring 
to inhibition of it.18,19
Our data show that the ECM has a magnificent role in 
the maintenance of tumor cell proliferation. Sarcoma cells, 
themselves, synthetize ECM components.13,14 The EHS-ECM 
(ECM derived from Engelbreth-Holm-Swarm [EHS] tumor) 
and the OSCORT-ECM (ECM produced by the OSCORT 
osteosarcoma cells) caused a significant increase of tumor 
cell proliferation and more extensive migration.5 For the 
mechanism by which ECM augments cell growth and pro-
liferation, we presume that it aids the transition from the G1 
to the S phase of the cell cycle. This suspicion is supported 
both by our flow cytometry and the protein expression results 
concerning increase of cyclin D1 and low decrease of Rb and 
p53 expression.5,15 PCNA, a marker for S phase, detected in 
culture on ECM gel, was complexed with other proteins. The 
second regulation point where ECM and its components may 
help the cells to get through the cell cycle control points is 
the checkpoint at G2/M. In our osteosarcoma cell line, we 
observed a decrease of the proportion of cells staying in this 
point, which is also a sign of increased proliferation. This 
is underscored by the increase of cyclin B1 and increase 
of topoisomerase II activity.5,15 The latter enzyme is most 
active in the G2/M phase.16 Another confirmation of this 
presumption is the stimulation of type IV collagen on Ki-67 
production. It is known that the Ki-67 protein is a prolifera-
tion marker of G2/M phase.17
Tumor dormancy and resistance to cytotoxic agents are 
key limiting events in the treatment of malignant diseases. 
Recent results suggest that the primary rate-limiting step 
in metastasis is not always the early cell destruction in the 
circulation or the inability of cells to extravasate, but it could 
be also due to the failure of extravasated cells in the target 
organ to initiate growth and failure of micrometastases to 
continue growing.20 Most cells successfully extravasate, but 
95% remain dormant, possibly revealing a substantial role 
of the new microenvironment in growth regulation. Since 
cytotoxic agents preferentially act on highly proliferating 
cells, tumor dormancy and loss of drug susceptibility are 
inversely related. Dormancy has been attributed by some to 
avascularity resulting from balanced proliferation and apop-
tosis, sequestration, absence of growth factors or hormones, 
or immunologic mechanisms.13,21 Our results suggested that 
ECM plays an important role in the development of a certain 
type of tumor dormancy. The inhibition of this process would 
be a therapeutic target, and our model might prove useful for 
exploring molecular mechanisms implicated in drug resis-
tance and in testing compounds to circumvent it.13
eCM controls cell migration  
and metastasis
The critical role of ECM in tumor migration and metastasis 
has been based partly on the expression of the ECM receptors 
(integrins) on the surface of the tumor cells and on the abil-
ity of the tumor cells to degrade the current ECM by matrix 
metalloproteinases (MMPs).22–25 Based on our investigations, 
remarkable tumor cell migration was associated with the 
elevated expression of β1 integrin as well as MMP-9 and 
MMP-2.14
Migration and metastasis
It was a further noteworthy observation that migration of 
osteosarcoma cells into the ECM gel was accompanied by 
an elevation of topoisomerase II activity, the target molecule 
for doxorubicin. As topoisomerase II showed higher levels of 
expression and activity in the migrating cells relative to the 
proliferating monolayer, it was of interest to study whether 
the two subpopulations are affected at the same extent by 
doxorubicin as an inhibitor of topoisomerase II.5 Doxorubicin 
caused a similar reduction in the activity but a difference 
in the lowering of protein expression of topoisomerase II 
in the non-migrating and in the migrating cells. Nevertheless, 
assuming the critical function of topoisomerase II in tumor 
invasion, it is conceivable that it could offer a molecular 
target for the selective antimigratory effect of doxorubicin 
applied in a low concentration for a long period. This eleva-
tion of topoisomerase II in cells migrated to ECM gel may 
indicate increased transcription, DNA synthesis, and repair 
functions, since this is one of the enzymes responsible for 
maintenance of the genome. We assume that the ECM-
induced elevation of topoisomerase II may be an underly-
ing event in the reprogramming of the gene expression, 
which is necessary for the invasive growth. The detected 
“topoisomerase-switch” in relation to tumor ECM-induced 
growth means elevation in topoisomerase II and reduction 
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in topoisomerase I activity. It was also induced by heparan 
sulfate PG (HSPG).5
We found that OSCORT-ECM also supported the inva-
sive growth of a human osteosarcoma cell line. This support 
was in association with the induction of β1 integrin and 
MMP-9 enzymatic activity, and was related to the suppres-
sion of topoisomerase I and enhancement of topoisomerase 
II activities.5
Tumor cells may migrate alone (ovarian cancer cells) 
or in the form of a cluster (osteosarcoma cells). The ECM 
morphology is different in these two types of migration.26–32 
The Boyden chamber and the three-dimensional cell culture 
(3-DCC) differentiate the antimigratory action of test com-
pounds against tumor.32,33 The Boyden chamber provided a 
model for single-cell migration and a 3-DCC system for clus-
ter migration.33,34 Investigations with Boyden chamber and 
3-DCC models help with finding agents which have the abil-
ity to inhibit the activity of PGs, integrins, and MMPs.32
MMPs and their inhibitors
Higher expression of MMPs was associated with severe 
symptoms, increased tumoral size, and worse grade. MMPs 
and their inhibitors have been identified as critical modula-
tors of ECM composition and are thus crucial in tumor cell 
progression, invasion, and metastasis.14 MMPs are members 
of the metzincin family of proteases, and they are respon-
sible for processing ECM components to respond to physi-
ological regulators or pathological impacts. Nevertheless, 
uncontrolled activity of MMPs results in alteration in the 
biological function of ECM biopolymers by degrading the 
ECM of basement membrane. In addition, the concomitant 
release of cytokines and growth factors from the degraded 
ECM accelerates tumor progression.
The elevation of MMP-9, which is responsible target for 
the cluster-type migration, correlates with the higher invasive 
capacity of neoplastic cells.30 Reports on the elevated MMP 
activity in human tumors have stimulated attempts to identify 
MMP inhibitors for many years.14 Although MMPs were 
considered an attractive target for therapeutic intervention, 
recent clinical trials did not fulfill the expectations. Data from 
clinical trials with the MMP inhibitor batimastat (BB-94) in 
the 1990s emphasized the need for better understanding of 
the complexity of MMP activity and the consequences of its 
suppression in tumor growth.35 Later results have provided 
data for the multiple roles of MMPs, thereby tumor pro-
gression and metastasis could be not only inhibited but also 
promoted after treatment with an MMP inhibitor depending 
on the function of the affected ECM protein. Since certain 
ECM components have tumor growth-controlling potency, 
their degradation must be avoided. This situation has opened 
avenues for a strategy involving the normalization of the 
tumor microenvironment as a novel therapeutic approach 
to cancer treatment.36 Endostar, a human recombinant 
endostatin decreases MMP expression. This inhibitory effect 
could be correlated with the reduced migration and invasive 
growth of MDA-MB-435 cells through reconstituted ECM.37 
At present, the concept recognizes MMP inhibitors acting 
against a signal mechanism implicated in the induction of 
MMPs. MMP-9 expression is reduced by oroxylin A (a bio-
active flavonoid) through the inhibition of extracellular 
signal-regulated kinase (ERK)1/2, which resulted in the 
control of metastasis in animal models.38
ECM biopolymers and their 
inhibitors
The biopolymers of ECM (ECM biopolymers or ECM com-
ponents) appearing in tumors were reported to have a priming 
function in microenvironment for cancer development and 
metastasis. The interaction of tumor cells and ECM compo-
nents is profoundly altered at all stages of tumor progression. 
The microscopical injuries of basement membrane are signs 
of invasive growth of tumor.6,39
The ECM biopolymers are classified as polysaccharides 
and fibrous proteins and are localized either in the intersti-
tial space or in the well-defined morphological entry of the 
basement membrane surrounding epithelial cells. Basement 
membrane is built from laminin and collagen IV networks 
stabilized by nidogen/perlecan bridges.6 In tumor biological 
studies, the most well documented ECM polysaccharides 
are the glycosaminoglycans (GAGs), which usually link to 
proteins forming PGs such as perlecan, decorin, agrin, and 
syndecan HSPGs. These PGs have two important character-
istics: the hydrophilic property and the ability to store and 
transmit growth factors. The other main groups of ECM 
biopolymers, the family of the fibrous proteins, include col-
lagen, laminin, and fibronectin.
The ECM proteins have been classified as a family of 
nonstructural matrix proteins, and they are a crucial com-
ponent of tumor microenvironment because they not only 
represent a structural element in tissue organization, but also 
have an active role in the maintenance of malignant pheno-
type. This implies that transformed malignant cells are, to 
a certain extent, under the surveillance of ECM proteins as 
well. These proteins induced by either tumor cells or tumor 
stromal components initiate downstream signaling events 
that lead to proliferation, invasion, matrix remodeling, and 
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Figure 1 Cellular regulation mediated by extracellular matrix (eCM).
Notes: The action of eCM components on the major signaling pathways of tyrosine kinase receptors, their links, and the outcome on tumor cell and chemotherapeutic 
response. inhibition or activation of potential sites could be used for therapeutic intervention in anticancer treatment. The eCM proteins and proteoglycans, directly or 
after binding to integrin receptors, through PI3K/AKT/mTOR (yellow) and RAS/RAF/MEK/ERK (purple) pathways, significantly influence cell proliferation, apoptosis, and 
response to chemotherapeutic drug. The Pi3K/AKT/mTOR pathway plays a role in regulation of p53 activity and apoptosis and controls critical proteins involved in tumor 
cell proliferation and migration. The pathway is also connected to the wnt/β-catenin pathway, among many others. As a response to eCM biopolymers, the mTOR kinase 
regulates translation of protein synthesis of some key molecules such as cyclin D1, p27, pRb, and c-Myc. mTOR inhibitors suppress the translation of mRNAs involved in 
cell growth and migration. The RAS/RAF/MeK/eRK pathway can also be activated by eCM components. Phosphorylated eRKs get activated and will be translocated into the 
nucleus, where they phosphorylate further transcription proteins, such as Fos, elk-1, CReB, and Gata-1. These transcription factors bind to promoter regions of many genes, 
like growth factor and cytokine genes, which are important in promotion of growth and prevention of apoptosis in case of different cell types. Mutations in the tumor often 
activate the Pi3K/AKT/mTOR and RAS/RAF/MeK/eRK pathways. inhibitors targeting these pathways could be successfully combined with chemotherapeutic drugs and/or 
radiotherapy that inhibit rapidly growing cancer cells.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1390
Harisi and Jeney
dissemination (Figure 1). As the architecture of the tumors 
show remarkable diversity, the composition and the amount 
of ECM proteins differ from normal tissue and allow novel 
interactions to influence tumor cell function.40 The accu-
mulated data from numerous relevant studies suggest that 
basic behavior of tumor cells, including altered intercellular 
contacts, invasive growth, and metastasis, can be associated 
with the dysregulated ECM proteins. Modification of these 
events of tumor microenvironment could lead to potential 
new methods of tumor therapy.5
A brief introduction to the expression and cellular func-
tions and also the enzymatic degradation of ECM proteins 
intends to offer an insight into the relevance of ECM proteins 
as a promising target for antitumor agents.
Collagen
Collagen represents the main ECM protein in tumors as well as 
in normal tissues. The elevation of collagen is a risk factor in 
the development of breast carcinoma. In the metastatic process, 
collagen facilitates cluster formation for the spreading tumor 
cell. In animal models, it was also confirmed that increased 
stromal collagen significantly increased tumor formation and 
results in a more invasive phenotype.32,41,42 In our investigations, 
type IV collagen decreased proliferation5,15 – interestingly, not 
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because of decreased adhesivity of the cells, since our experi-
ments with type IV collagen-coated culture dishes showed 
greater adhesivity of the cells to type IV collagen than to 
poly-l-lysine. Inhibition of melanoma cell proliferation was 
previously reported for a distinct domain of type IV collagen: a 
fragment of alpha3 chain (C-terminal amino acids: 185–203).43 
The background of cell growth decrease upon addition of type 
IV collagen to the culture medium, on the other hand, is likely 
due to cell cycle arrest in the G2/M phase.44,45 Collagen type IV 
inhibited the invasive growth of osteosarcoma. The elevation 
of topoisomerase II activity was related to the accumulation 
of osteosarcoma cells in the G2/M phase.5 Diphosphorylated 
active ERK2 phosphorylated topoisomerase IIα and increased 
its specific activity sevenfold, as recorded by DNA relaxation 
assays.5,46 ERK2 is activated by mitogen-activated protein 
kinase 1/2 (MAPK 1/2), which is the target of collagen IV-
mediated signaling.5,47 Collagen environment controls the Wnt 
pathway.5,48
Laminin
The laminin family of glycoproteins is an important 
constituent of basal lamina, which forms networks to stabilize 
adhesion of cells. Laminins bind other ECM components 
such as collagen, nidogen, and entactin. The laminins influ-
ence cell differentiation, migration, and viability of tissues.49 
Serving as an early and useful model of tumor cell–ECM 
interactions is the human fibrosarcoma cell line (HT1080).50 
Due to the in vivo infiltrative growth of a fibrosarcoma, it 
inevitably interacts with ECM components at the site of 
intra- and extravasation. HT1080 cells adhere strongly to 
laminin-1 and laminin-5 utilizing both α3β1 and α6β1 
integrins and can attach to collagen I and fibronectin using 
α2β1 and α5β1 integrins, respectively.51 Under appropriate 
conditions, rapid HT1080 cell aggregation leads to the for-
mation of extensive cellular networks.13 Rather than being 
evidence of a malignant phenotype, network formation may 
more precisely be related to basement membrane-induced 
cell motility and can be observed in normal primary cell 
culture.50,52 On the contrary, our results concerning lack of 
laminin effect on osteosarcoma cell proliferation, while it 
enhanced β1 integrin production, might be explained by 
Kawaguchi and Uede: the decreased expression of laminin 
receptors in human osteosarcomas.53
Fibronectin
Fibronectin, a glycoprotein, binds to ECM and enhances its 
binding to integrins. Fibronectin expression is elevated in 
poorly differentiated tumors, where it has a major role in tumor 
growth and migration, which could either be due to increased 
fibronectin production by the more anaplastic tumor cells or 
internalization of exogenous fibronectin bound to its receptor.54 
Several mechanisms of cell growth control were clarified dur-
ing the last few years, in particular the negative regulation of 
integrin activation by RAS/RAF and the TGF-β inhibition 
of p33cdk2 phosphorylation and cyclin A- and E-associated 
histone H1 kinase activities.55,56 Another model of growth 
inhibition resulting in dormancy of human carcinoma Hep3 
cells is the reduced urokinase plasminogen activator receptor 
(uPAR) level leading to a reduced avidity of the α5β1 integrin 
and a lower adhesion of cells to fibronectin.57 In our results, 
it seems that from ECM biopolymers, in case of osteosar-
coma, HSPG and fibronectin provide a stimulatory signal 
for the tumor, for increased proliferation observed on ECM 
gel.5 These two components are not more than 10% of ECM 
gel but may trigger signal routes resulting in increased cell 
reproduction.58,59 Kawaguchi and Uede examined cell surface 
receptors of human osteosarcomas.53 They found the integrins 
that bind to fibronectin: α4β1 in 100% of the cases, and α5β1 
in 75% of the cases. β1 integrin complexes are known to inter-
act with fibronectin, which explains the increased growth of 
OSCORT cells in fibronectin-containing medium.
Periostin
Periostin, a multifunctional matricellular protein, has been 
detected at elevated levels in tumors and demonstrated its 
active contribution to tumor progression.60
PGs, heparanases, and inhibitors
PGs – synthetized in both parenchymal and stromal cells – 
consist of a “core protein” in which serine residues are 
covalently linked to GAG through a tetrasaccharide bridge. 
GAGs, mainly heparan sulfate or chondroitin sulfate, are 
long linear polymers, which are negatively charged due to the 
sulfate groups. PGs have an important role in cell–cell and 
cell–ECM interactions and signaling. The complex structure 
of PGs allows their participation in a variety of cellular func-
tions (motility, adhesion, growth).5 However, the individual 
PGs (perlecan, syndecan, decorin) have distinct mechanisms 
and, in certain cases, opposite cellular action.
The GAG chains recognize “binding” motifs of the 
ECM components, including integrins and receptors. The 
participation of heparan sulfate as a receptor in endocytosis 
is notable. The storage and transport of growth factors is a 
rather important function of PGs, because it may be viewed 
as a rate-limiting process in signaling mechanisms. Recent 
studies provided evidence for the translocation of syndecan-1 
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(Sdc1), glypican, and perlecan into nucleus. In another study, 
the reduced topoisomerase I activity and inhibition of gene 
transcription were documented.61,62
PG structures are substrates of heparanase, which cleaves 
the β(1,4)-glycosidic bond between glucuronic acid and 
glucosamine residue, releasing heparan sulfate polymer with 
a shorter chain length. Besides the remodeling of the ECM, 
uncontrolled heparanase activity also results in an extended 
release of many HS-linked molecules similarly to growth 
factors, cytokines, and enzymes, which contribute to various 
pathological conditions. In fact, heparanase regulates HSPG 
Sdc1 shedding from the cell surface, which promotes tumor 
growth and metastasis.
In tumors, changes in the expression and degradation 
of the PGs contribute to the altered composition of ECM 
and result in abnormal PG function. PGs after the structural 
changes may have altered biological effects. On the basis of 
the above data, it has been proposed that PGs may be poten-
tially useful as molecular markers for cancer personalized 
diagnosis and therapy.63
Syndecan and glycosylphosphatidylinositol-anchored 
glypican are the major, and betaglycan and V-3 isoform of 
CD44 the minor, compounds of membrane HSPGs. In the 
ECM, and especially in basement membrane, the multi-
domain perlecan, agrin, and collagen XVIII core proteins 
are the main heparan sulfate-bearing species. HSPG con-
tributes to development of malignant phenotype and tumor 
progression.5,15 Alterations of HSPG represent the most 
tumor-specific changes in the ECM structure. It depends on 
the variability of the heparan-sulfate synthesis.5,24
Perlecan and agrin
Perlecan is a multidomain HSPG PG that binds to and cross-
links many ECM components and cell-surface receptors. 
Perlecan as a constituent of basement membrane is affected 
by growth factors when tumor cells cross this barrier.64 
HSPGs were proved to have regulatory roles.65–68 Perlecan’s 
expression reduces in vitro the tumor cells formed by larger 
colonies. Enhanced perlecan release causes faster growth in 
nude mouse cells compared to wild-type tumor cells. A low 
perlecan level substantially inhibits the growth of nude mouse 
tumor cells.65–68 The HSPGs, including perlecan, act as pro-
moters or suppressors for proliferation, migration, and inva-
sion of the tumors.5,69 It is well known that the Wnt/β-catenin 
pathway is involved in the regulation of cell migration, and 
HSPGs are important regulators of this signaling pathway.5,67 
HSPGs induce the expression and activity of topoisomerase 
II through the stimulation of ERK2 and via integrin-mediated 
signaling to the Wnt signaling pathway.5,46,48,70–72
HSPG is the most active ECM component for increased 
proliferation and migration of human OSCORT osteosar-
coma cells. That is why its inhibition could be a target in 
the treatment of metastatic osteosarcoma.5,14 These results 
are in line with findings referring to HSPG’s multiple role 
in tumor invasion.5
Agrin, another HSPG, is involved in neuromuscular 
differentiation and synaptogenesis, as well as being a con-
stituent of renal glomerular basement membrane.5 We have 
found that agrin is also present in the osteosarcoma tumorous 
ECM.5 This was the first time that the presence of agrin in 
a tumor was verified.5 Agrin was the only HSPG present in 
ECM of OSCORT osteosarcoma cells.5 Tumorous ECM is 
important in supporting the metastatic ability. The stimula-
tory effects of HSPG might be attributed to heparan sulfate 
chains belonging to agrin.5,14 A potential of the Wnt/β-catenin 
pathway to crosstalk with the agrin signaling cascade has 
also been reported.5,70
Syndecan
Transmembrane HSPGs have the capacity to interact with a 
large number of ligands and receptors from the Sdc1.
Docking sites in the syndecan extracellular domains cap-
ture αvβ3 integrin and insulin-like growth factor 1 receptor 
(IGF1R), forming a ternary receptor complex which initiates 
signaling downstream of IGF1R. It is noteworthy that a pep-
tide inhibitor called synstatin derived from a mutant syndecan 
can competitively displace the αvβ3 or αvβ5 integrin and 
IGF1R kinase from the syndecan.73,74
Decorin
Decorin is a small, leucine-rich cellular or pericellular 
matrix PG and binds to type I collagen fibrils. In contrast to 
syndecan, decorin acts as a tumor repressor by interfering 
with the PDGF signaling pathway.75 Upregulation of deco-
rin A549 tumor cells resulted in decreased TGF-β1, cyclin 
D1 expression, and phosphorylation of EGFR, but higher 
levels of p53 and of p21 (Waf1/Cip1). The changes of these 
signaling molecules could be correlated with the decreased 
invasive growth and cell cycle blockage at G1.76,77
The expression of CCN1, a secreted matrix-associated 
molecule, has been reported to correlate inversely with the 
aggressiveness of non-small-cell lung carcinoma; recombi-
nant CCN1 protein led to a permanent cell cycle arrest in 
G1 phase.
The phenotype characteristic of senescent cells is influ-
enced by abundance of hypo-phosphorylated Rb, accumula-
tion of p53 and p21 (Waf1/Cip1) and senescence-associated 
β-galactosidase.78
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Heparanase
Heparanase cleaves heparan sulfate and participates in 
degrading and remodeling the ECM. Since a high level of 
heparanase in tumor was shown to correlate with distant 
metastasis and reduced survival of cancer patients, hepara-
nase and its inhibitors have been listed among the targets of 
antitumor agents.79
The following heparanase inhibitors are documented in 
detail:80,81
1. PI-88 contains a mixture of highly sulfated, monophos-
phorylated mannose oligosaccharides.
2. Oligomannurarate sulfate (JG3), a novel marine-derived 
oligosaccharide, inhibited tumor angiogenesis and metas-
tasis by combating heparanase activity.
3. RK-682 was found to display inhibitory activity against 
heparanase.
4. The selective inhibition of heparanase with 4-benzyl-(R)-
3-hexadecanoyl-5-hydroxymethyltetronic acid has been 
demonstrated to display anti-invasive activity.
5. PG545, a tetrasaccharide heparan sulfate, shows affinity 
for heparanase a clinical anticancer candidate.
GAG biosynthesis and FAF inhibitors
Taking into account the importance of GAG chains in the bio-
logical action of PGs, small molecular compounds related to 
carbohydrate metabolism were investigated as putative GAG 
inhibitors. In tumor cell cultures, beta-d-xyloside, 2-deoxy-
d-glucose, ethane-l-hydroxy-l,l-diphosphonate, and 5-hexyl-
2-deoxyuridine (HUdR) induced reduced incorporation of 
[14C]-glucosamine into GAG, but to varying degrees. The 
most effective HUdR at 15 μg/mL concentration selectively 
inhibited GAG relative to other glycoconjugates.82,83
The first studies on the antimetastatic efficacy of HUdR 
aimed to compare the highly metastatic variant of LLT3 tumor 
containing elevated PG concentration with the parent tumor. 
The significant reduction in the metastatic nodules in the lung 
indicated an inverse correlation with GAG concentration and 
metastatic potency. However, in the subsequent experiments, 
the metastatic pattern of the mice transplanted intracardially 
with the HHLLT3 tumor showed an organ-specific action of 
HUdR as the number of metastatic nodules decreased only in 
the lung and kidney but not in the liver.84 Table 1 describes 
the antimetastatic action of HUdR.
Integrins as ECM receptor
integrin-mediated signaling
The multiple attachments of ECM biopolymers to the cell 
surface are executed mainly from a family of transmembrane 
adhesion receptors composed of non-covalently linked α 
and β subunits. The 18 α and eight β subunits form around 
24 unique integrins, which have a ligand-binding region at 
the cell surface for the ECM biopolymers. Integrins on the 
cell surface in a distinct activation state represent different 
affinities for ECM biopolymers. They are responsible for 
the formation of the dynamic contacts among the cellular 
and macromolecular elements of a tissue. In addition, the 
extracellular signal transduction, as an essential process 
for the cells, is mediated by the integrins. Several cellular 
signaling pathways are initiated from the integrins toward 
cytoskeletons for migration and also to the RAS/MAPK and 
PI3 kinase/mTOR pathways for survival. The outcome of 
the signal mechanisms are influenced by the correct linkage 
between ECM biopolymer and integrin. Survival pathways 
may be activated providing the appropriate ligand–integrin 
complex has been formed and stimulated by the relevant 
growth factor.5,14,32 Conversely, faulty, deficient, or blocked 
integrin ligand complexes can promote apoptosis under 
otherwise permissive growth conditions.
Integrin-linked kinase and focal adhesion kinase are key 
components of the signal transduction pathway triggered 
by integrin receptors to control cell growth, invasion, and 
survival.
integrins in tumor progression
The invasion of cancer cells in tumor progression is mainly 
regulated by their proteolytic remodeling of their surrounding 
ECM and by their integrin expression. The expression of the 
actual member of the integrin family in healthy conditions is 
mostly tissue/cell-specific, whereas, in pathological lesions, 
remarkable changes could be seen, including cancer. Integrin 
Table 1 The effect of HUdR on the metastasis formation of 3LL-
HH tumor cells injected into the left ventricle
Organ Number of metastatic nodulesa
Controls
(mean ± SE)
HUdR-treatedb
(mean ± SE)
Heart 8.1±1.51 7.4±1.73
Lung 28.8±4.43 8.3±1.81*
Liver 187.3±27.60 143.4±26.53
Brain 0.4±0.27 0.8±0.25
Kidney 87.5±7.00 24.2±4.16*
Adrenal gland 2.0±0.00 1.9±0.90
Stomach 24.5±2.81 18.5±2.38
Muscle 30.5±2.07 13.2±1.55*
Skin 7.0±2.20 1.7±0.56*
Notes: 2×104 3LL-HH cells were transplanted intracardially in C57Bl mice. each 
experimental group comprised ten mice. aNumber of metastatic nodules per mouse. 
b75 mg/kg HUdR was given four times intraperitoneally before tumor transplantation. 
*Significant (P,0.05) compared to controls.
Abbreviations: HUdR, 5-hexyl-2-deoxyuridine; Se, standard error.
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expression exhibits considerable heterogeneity according to 
tumor origin. Proliferation and invasion of many tumors have 
been associated with the overexpression of integrins.
The receptors for the extracellular signals providing 
increased proliferation of the cells are presumed to be inte-
grin molecules, mainly β1 integrin-containing complexes.85 
As previously described, osteosarcomas produce β1-integrin 
complexes (α2β1, α3β1, α4β1, α5β1), and β-1 integrin could 
be induced by ECM biopolymers in human osteosarcoma cell 
culture.5,86 There was a linear correlation between β1 integrin 
production and cell proliferation.85,87
The αv subunit was generally moderately to highly 
expressed in most tumors; nevertheless, the integrin profile 
may be modulated by the microenvironment. It was reported 
that αvβ8 binding to type I collagen activated the MEK/ERK 
signaling pathway.88
The high expression of integrins αvβ3 and αvβ5 was pro-
posed as a prognostic and diagnostic marker and therapeutic 
target for gastric cancer.89 High expression and activation of 
αvβ3 integrin was recognized in growing tumor vasculature 
and has correlated with the most metastatic and invasive 
breast tumors. Since tumor cells are exposed by a variety of 
ECM biopolymers during metastasis, for survival, their inte-
grin profile must adapt to the new environment. Therefore, 
it is important to collect data about the expressed integrin 
profiles of tumor metastases. At the first step of peritoneal 
dissemination, ovarian carcinoma cells enhanced expression 
of α2β1 integrin that was related to spheroid disaggregation 
and proteolysis.90
In the permanent migratory capacity of tumor cells, 
the fibronectin-binding integrins, such as αvβ3, have been 
suggested to have an important function in metastatic renal 
cell carcinomas and melanomas. αvβ3 and cytoplasmic β3 
were weakly to moderately detectable. In addition, αvβ5 
was prominently expressed in metastatic renal and colorectal 
carcinomas. Interestingly, in metastatic lung adenocarcino-
mas, αvβ6 was the most abundantly detectable integrin, but 
was absent in melanomas. Thus, the dominant integrins in 
metastatic tumors show certain heterogeneity.
integrin inhibitors
Some integrins (αvβ3, αvβ5, αvβ1, αIIbvβ3) interact with 
ligands of ECM containing the Arg-Gly-Asp sequence (RGD 
sequence).
Cilengitide is a cyclic RGD peptide (cyclo arg-gly-
asp-D-Phe-1-amino cyclohexane carboxylic acid) and was 
reported to reduce invasiveness of melanoma cells through 
the inhibition of αvβ5 integrin.91
Another integrin inhibitor, S247 is a small peptidomi-
metic antagonist of αvβ3 and αvβ5 integrins, and it is able 
to inhibit lung metastasis in mice.
Recently, humanized monoclonal antibodies have been 
developed to inactivate integrin αv and α4β7. Abituzumab 
targeting integrin αv heterodimers has demonstrated preclini-
cal activity. Vedolizumab binds to the α4β7 integrin complex 
and inhibits adhesion of certain molecules.92
Salvicine, a modified diterpenoid quinone, inhibited the 
adhesion of human breast cancer MDA-MB-435 cells to 
fibronectin and collagen. Salvicine downregulated β1 integrin 
ligand affinity, clustering and signaling via dephosphoryla-
tion of focal adhesion kinase.93
Secreted threonyl-tRNA synthetase stimulates cell 
migration. This enzyme could be inhibited by borrelidin, 
showing selective antimigratory and antimetastatic effects 
in several animal models. In vitro antimigratory efficacy of 
borrelidin was attenuated in the presence of ECM proteins, 
preferentially by fibronectin. This observation demonstrated 
the selective reduction of expression of integrin αvβ5, 
because α2, α3 and β1 subunit were not affected in borrelidin- 
treated tumor cells.5,94,95
ECM as modulator of 
chemotherapeutic drug efficiency 
and as target in antitumor treatment
It is well known that ECM remodeling is crucial for tumor 
malignancy and metastatic progression.13,14,87,96 However, the 
further question arises whether ECM could provide protection 
against chemotherapeutic drugs and contribute to tumor cell 
repopulation after the treatment. A large number of experiments 
have provided evidence that apoptosis induced by chemothera-
peutic agents is suppressed in the presence of ECM.14,69,97,98 
Failure in antitumor therapy is mostly due to repopulation of 
the surviving tumor cells. In this respect, the repopulation is 
viewed as a continuing proliferation of cells with the capacity 
to regenerate the tumor shrinkage after anticancer treatment.69 
ECM promotes both a “dormant-like” state and increases resis-
tance of certain tumor cells to cytoreductive treatment, thereby 
modeling two key processes that limit tumor medication.13,69
Studying ECM and ECM biopolymers is an important 
requirement of successful anticancer therapy. Nevertheless, 
ECM-mediating pathways are not well modeled in classical 
cell culture systems.13,14 The ECM gel used model provides 
an extracellular matrix-based culture system (3-DCC) as an 
alternative option to the conventional plastic cell culture. 
Using this system, the protective effect of ECM against 
cytotoxic damage is recognizable.13,14
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In the presence of ECM (ECM gel), a reduction of chemo-
therapeutic drug-induced apoptosis was detected in glioma, 
myeloma, and small-cell lung cancer cells.99 Stromal ECM 
provides protection against cytotoxicity of topoisomerase 
poisons in colon tumor cells and small-cell lung cancer 
cells.100 This is achieved by stimulation of protein tyrosine 
kinase (PTK) and/or inhibition of caspase-3 activation.100
In the case of osteosarcoma, clinical trials did not show 
any survival benefit following intensified therapy in poor 
responders.101 It was found that dynamic ECM remodeling 
is involved in the chemotherapy resistance of osteosarcoma.5 
It includes bone degradation and, simultaneously, synthesis 
of novel, modified, tumor-specific ECM.5 In the presence of 
tumorous ECM, the apoptotic index, the parameters of the 
comet assay and the expression of p53 were lower.69 The 
detected reduction of apoptosis has been associated with 
a decrease of bax expression. This lowering is due to the 
invalidation of p53 cell nuclear localization.69 This event 
was induced by the tumorous ECM.15 Decreased p53 protein 
synthesis correlated with increased survival and decreased 
apoptosis of tumor cells following doxorubicin treatment.15 
ECM can increase the repair capacity of cells and may con-
tribute to increased repair after cytostatic damage.69,102 Since 
DNA damage occurs subsequent to radiochemotherapy, the 
above data provide further evidence for ECM-enhanced 
repair.13
Up to now, anticancer drug research has focused on 
inhibition of a tumor growth, and a little attention was paid 
to controlling tumor cell migration.32,33 The antimigratory 
effects of drugs can be well investigated by newly developed 
assays.14,32 The Boyden chamber in combination with the 
3-DCC ECM-based model makes it possible to differentiate 
between single-cell or cluster-type migration.14,32 Our data 
provide evidence that there are cytotoxic/cytostatic agents 
which, depending on concentration, preferentially inhibit 
migration compared to proliferation.32,33 Taxol, a widely used 
anticancer drug, selectively inhibits the single-cell migration 
when it is used at a very low, subtoxic concentration.32,33 
Depending on microenvironment or antitumor treatment, 
tumor cells switch their mechanism of migration and there-
fore escape the effect of applied drug.14 Since doxorubicin 
inhibits cluster-type migration at subtoxic concentrations, the 
combination of Taxol with doxorubicin offers a possibility 
of acting against both single-cell and cluster-type tumor cell 
migration.32,33 Therefore, successful antimetastatic therapy 
will be achieved when agents acting against single-cell and 
cluster-type migration become weapons in the arsenal of 
clinical oncology.32,33
Concluding remarks
The drastic structural alteration in tumor microenvironment 
was recognized more than 100 years ago. Its relevance in 
tumor development and progression has been understood 
only in the last two decades. A large body of evidence has 
been accumulated that indicates matrix proteins are basic con-
stituents of the extracellular space and that their cell surface 
receptors, mainly integrins, have an active role at all steps of 
tumor progression. This participation of ECM includes the 
uncontrolled cell proliferation, disruption of cellular interac-
tion, migration, and settlement in remote organs. ECM is not 
only a major component of tumors, but also a contributor 
to the transformed phenotype by reprogramming cellular 
phenotype. ECM provides cues that promote proliferation 
and migration. Considering all the complex impact of matrix 
proteins and PGs surrounding the malignant cells, it has been 
suggested that ECM acts as a driving force in tumor progres-
sion and represents a novel perspective for examining the 
prognosis and developing therapeutic agents. Composition 
of ECM in tumors not only differs from in normal tissue, 
but also shows great heterogeneity among various tumors, 
which allows the classification of tumors according to their 
ECM profile. As a matter of fact, the structural and functional 
changes in tumorous ECM may not be viewed as a reactive 
response exclusively by the host because gene expression 
of ECM components was modified both in neoplastic and 
stromal cells.8
The clinical studies indicate that high expression of 
integrins and metalloproteinases predicted poorer progno-
sis, whereas low expression of laminin chains represented 
a rather favorable outcome. Since preclinical and clinical 
studies demonstrated the multiple mechanism by which the 
various ECM components constantly exert a driving force 
on the progression of tumors, the question has been raised 
whether the ample knowledge may be utilized in antitumor 
therapy. Certainly, to design drugs selectively targeting ECM 
represents an attractive actual and novel approach, but raises 
several unresolved problems. The ECM components, such as 
decorin and syndecan, exert opposite actions on proliferation; 
similarly, PGs, after loss of their carbohydrate chain, show 
different biological activity. Perhaps the most severe limiting 
aspect is the duality in the function of some ECM-associated 
molecules, as was revealed when loss of β1 integrin attenu-
ated breast tumor growth but markedly enhanced tumor cell 
dissemination.103
These circumstances explain the modest steps in the tran-
sition of the results from preclinical studies on ECM-targeted 
anticancer therapy into clinical practice. Presently, it is worth 
OncoTargets and Therapy 2015:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1396
Harisi and Jeney
focusing on agents that act on heparanase and proteases, 
which restructure ECM. In addition, there are noteworthy 
clinical experiences with cilengitide inactivating αvβ3 and 
αvβ5 integrins. Furthermore, the inhibition of GAG offers 
another promising approach in the treatment of those tumors 
which are stimulated by PGs. In spite of all the difficulties, 
ECM must be considered as a highly rewarding target in 
tumor therapy, because nearly all steps in the metastatic 
process – ie, disruption and adhesion in intercellular contacts, 
migration, and settlement – are controlled by the aberrantly 
operating tumor ECM.
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